Literature DB >> 20100647

Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.

M C Marzola1, M R Pelizzo, M Ferdeghini, A Toniato, A Massaro, V Ambrosini, S Fanti, M D Gross, A Al-Nahhas, D Rubello.   

Abstract

BACKGROUND: To evaluate the role of a multi-imaging PET with (18)F-DOPA and (18)F-FDG in comparison with conventional imaging (CI) in recurrent medullary thyroid carcinoma (MTC).
METHODS: 18 MTC patients who had thyroidectomy were included; they presented with elevated and rapidly increasing calcitonin levels during follow up. CI had revealed metastatic deposits in 9 patients. Patients were referred to us for a PET/CT with (18)F-DOPA and (18)F-FDG. Histologic/cytologic confirmation of recurrent MTC was obtained in at least one PET-positive lesion in all patients.
RESULTS: Foci of abnormal uptake were observed in 15 patients at (18)F-DOPA and in 11 at (18)F-FDG; 8 patients showed the same number of positive lesions with both tracers, 2 showed more lesions on (18)F-FDG, 1 was positive at (18)F-FDG alone and 5 at (18)F-DOPA alone. In 3 patients with a DOPA-positive loco-regional relapse a re-operation with curative intent was offered. SUV(max) values were higher for (18)F-FDG compared to (18)F-DOPA (mean 12.7+/-4.1 vs. 5.5+/-2.1, p<0.05). Calcitonin was higher in PET-positive patients compared to PET negative ones, while no significant differences were observed between (18)F-DOPA and (18)F-FDG positive patients.
CONCLUSIONS: In MTC patients with rapidly increasing calcitonin levels during follow up, (18)F-DOPA has a good sensitivity and a complementary role with (18)F-FDG PET/CT in detecting metastatic deposits. In our experience, the sensitivity of a multi-imaging (18)F-DOPA &amp;(18)F-FDG PET/CT approach is greater than that obtained with CI. The higher SUV(max) values found with (18)F-FDG in some patients may reflect more aggressive tumors. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100647     DOI: 10.1016/j.ejso.2010.01.001

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  16 in total

1.  Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma.

Authors:  Domenico Rubello; Ka Kit Wong; Maria Cristina Marzola; Mohsen Beheshti; Valentina Ambrosini; Sotirios Chondrogiannis; Milton D Gross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 9.236

Review 2.  Non-FDG PET in oncology.

Authors:  R Núñez Miller; M A Pozo
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

3.  SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

Authors:  Anna Margherita Maffione; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-22       Impact factor: 9.236

4.  EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma.

Authors:  Luca Giovanella; Giorgio Treglia; Ioannis Iakovou; Jasna Mihailovic; Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

5.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Authors:  Giorgio Treglia; Paola Castaldi; Maria Felicia Villani; Germano Perotti; Chiara de Waure; Angelina Filice; Valentina Ambrosini; Nadia Cremonini; Monica Santimaria; Annibale Versari; Stefano Fanti; Alessandro Giordano; Vittoria Rufini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-06       Impact factor: 9.236

Review 6.  Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.

Authors:  Giorgio Treglia; Maria Felicia Villani; Alessandro Giordano; Vittoria Rufini
Journal:  Endocrine       Date:  2012-04-17       Impact factor: 3.633

Review 7.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

8.  Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.

Authors:  Ana Reyes Romero-Lluch; Juan Ignacio Cuenca-Cuenca; Raquel Guerrero-Vázquez; Antonio Jesús Martínez-Ortega; Juan Luis Tirado-Hospital; Isabel Borrego-Dorado; Elena Navarro-González
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-23       Impact factor: 9.236

9.  (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.

Authors:  Aurélien Archier; Céline Heimburger; Carole Guerin; Isabelle Morange; Fausto F Palazzo; Jean-François Henry; Olivier Schneegans; Olivier Mundler; Ahmad Esmaeel Abdullah; Frédéric Sebag; Alessio Imperiale; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

10.  Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Friederike Schütz; Christine Lautenschläger; Kerstin Lorenz; Johannes Haerting
Journal:  Eur Thyroid J       Date:  2017-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.